299 related articles for article (PubMed ID: 16120852)
1. Patents versus patients? Antiretroviral therapy in India.
Havlir DV; Hammer SM
N Engl J Med; 2005 Aug; 353(8):749-51. PubMed ID: 16120852
[No Abstract] [Full Text] [Related]
2. [HIV antiretroviral agents: new threats to accessibility in developing countries].
Nau JY
Rev Med Suisse; 2005 Dec; 1(45):2956. PubMed ID: 16425957
[No Abstract] [Full Text] [Related]
3. Essential AIDS medications in India.
Thomas J
Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
[No Abstract] [Full Text] [Related]
4. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
Jain D; Darrow JJ
Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
[TBL] [Abstract][Full Text] [Related]
5. The Brazilian experiment: HIV drugs for all.
Flaer PJ; Younis MZ
J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
[TBL] [Abstract][Full Text] [Related]
6. Generic HIV drugs--enlightened policy for global health.
Wainberg MA
N Engl J Med; 2005 Feb; 352(8):747-50. PubMed ID: 15728804
[No Abstract] [Full Text] [Related]
7. Generic and branded drugs for the treatment of people living with HIV/AIDS.
Bartlett JA; Muro EP
J Int Assoc Physicians AIDS Care (Chic); 2007 Mar; 6(1):15-23. PubMed ID: 17329500
[TBL] [Abstract][Full Text] [Related]
8. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
9. TRIPS: generic irony.
Howarth GR
Br J Gen Pract; 2002 Jan; 52(474):57. PubMed ID: 11791819
[No Abstract] [Full Text] [Related]
10. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
11. . . . and Brazilian AIDS programme threatened by US trade action.
Int J Epidemiol; 2001 Apr; 30(2):413. PubMed ID: 11369751
[No Abstract] [Full Text] [Related]
12. Clinton brokers deal to lower price of antiretrovirals.
Abimbola S
BMJ; 2007 May; 334(7602):1026. PubMed ID: 17510129
[No Abstract] [Full Text] [Related]
13. India: New patent law may restrict access to HIV/AIDS treatments.
Cruess G
HIV AIDS Policy Law Rev; 2005 Aug; 10(2):28-30. PubMed ID: 16365971
[TBL] [Abstract][Full Text] [Related]
14. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
15. The global reach of HIV/AIDS: science, politics, economics, and research.
Gostin LO
Emory Int Law Rev; 2003; 17(1):1-54. PubMed ID: 16180288
[No Abstract] [Full Text] [Related]
16. 100th HIV/AIDS antiretroviral drug approved by PEPFAR.
AIDS Patient Care STDS; 2009 Nov; 23(11):988-9. PubMed ID: 19938372
[No Abstract] [Full Text] [Related]
17. Balancing pills and patents: intellectual property and the HIV/AIDS crisis.
Nderitu T
E Law; 2001 Sep; 8(3):E5. PubMed ID: 16903022
[No Abstract] [Full Text] [Related]
18. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
[No Abstract] [Full Text] [Related]
19. The production of generic drugs in India.
Love J
BMJ; 2011 Mar; 342():d1694. PubMed ID: 21427048
[No Abstract] [Full Text] [Related]
20. [The patent legislation in India fails the HIV/AIDS work].
Holen Ø
Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2666-7. PubMed ID: 16215618
[No Abstract] [Full Text] [Related]
[Next] [New Search]
